Employees: 38
Size IRulya Therapeutics (IRLA) is a United States Health Care company (Biotechnology) with a market value of $440M, the 2770th largest of 3,085 United States companies the cockpit tracks. Shares closed at $40.59 on 18 Nov 2026.
Performance Over six months the shares gained 87.9%, against -17.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 20 in its peer set.
Capital Return on invested capital runs 79.0 points below its cost of capital (14.0% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$131,000 | -$142,000 | -$186,000 | -$322,000 | -$175,000 |
| EBITDA | -$64.2M | -$50.3M | -$36.0M | -$24.3M | -$49.9M |
| Net income | -$107M | -$84.0M | -$56.8M | -$31.4M | -$51.7M |
| Free cash flow | -$46.9M | -$41.8M | -$32.2M | -$18.5M | -$44.2M |
| Capital expenditure | $75,000 | $352,000 | $257,000 | $160,000 | $133,000 |
| Total debt | $0 | $18.5M | $14.8M | $13.8M | $453,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IRLA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.8% | -12.7% | 2nd highest of 21 |
| 6-month return | +87.9% | -17.4% | highest of 20 |
| Distance from 52-week high | -95.5% | -39.7% | lowest of 21 |
| ROIC minus cost of capital | -79.0 pp | -6.0 pp | 3rd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | 3.3× | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 2.2× | 7.7% | +7.3% |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | 9.9× | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 4.0× | 2.1% | +0.5% |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | 3.1× | n/a | n/a |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 2.6× | -19.5% | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 12.3× | 5.3% | +70.5% |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 14.6× | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | 2.9× | 4.0% | -62.3% |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 509.6× | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | 215.1× | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | 908.6× | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | 10.6× | n/a | n/a |